Edward Smith - Conatus Pharmaceuticals Insider

Conatus Pharmaceuticals Inc -- USA Stock  

USD 4.3  0.02  0.46%

Senior Vice President - Regulatory Affairs and Quality Assurance

Dr. Edward F. Smith III., Ph.D. is Senior Vice President Regulatory Affairs and Quality Assurance of the company. He was Vice President, Regulatory Affairs and Drug Safety at Zogenix, Inc., since October 2008, which he joined as Senior Director, Regulatory Affairs in April 2007. Before joining Zogenix, he served as Senior Director, Regulatory Affairs at Connetics Corporationration from 2006 to 2007 Director, Regulatory Affairs at Nektar Therapeutics from 2004 to 2006 Director, Corporationrationrate Regulatory Affairs at Valeant Pharmaceuticals from 2001 to 2004 and Vice President, Regulatory Affairs and Research Development at Radiance Medical Systems, Inc., from 1999 to 2001. He previously held research and development positions at Mallinckrodt Inc. from 1992 to 1999, at SmithKline Beecham Pharmaceuticals from 1986 to 1992, and at CibaGeigy from 1984 to 1985. Dr.160Smith held postdoctoral fellowships at the Institute of Pharmacology at the University of Koln in Germany, and the Medical University of South Carolina
  President Since 2016  MBA    
858-376-2600  http://www.conatuspharma.com
#160;Smith received a B.S. in biology from Montana State University, a Ph.D. in physiology from Thomas Jefferson University, and an M.B.A. from Washington University. He also holds a Regulatory Affairs Certification.

Management Efficiency

The company has return on total asset (ROA) of (22.75) % which means that it has lost $22.75 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (74.5) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 12.97 M in liabilities with Debt to Equity (D/E) ratio of 41.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals Inc has Current Ratio of 2.64 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 6 records

PRESIDENT Since

Eyal BreitbartVascular Biogenics Ltd
2014
Erez FeigeVascular Biogenics Ltd
2014
Adam BuckleyVBI Vaccines Inc
N/A
T BuckleyVBI Vaccines Inc
N/A
Yael CohenVascular Biogenics Ltd
2008
Athena KartsaklisVBI Vaccines Inc
2017

Entity Summary

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Conatus Pharmaceuticals Inc (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 25 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio File Import Now
   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
Hide  View All  NextLaunch Portfolio File Import
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Conatus Pharmaceuticals Inc to your portfolio

Top Management

Conatus Pharmaceuticals Leadership Team
Edward Smith, President, MBA
Michelle Vandertie, Executive
Dan Kisner, Director
James Scopa, Director
Steven Mento, CEO
Daniel Kisner, Director
Preston Klassen, Director
David Hale, Chairman
Harold Wart, Director, Ph.D
William LaRue, Director, MBA
Alfred Spada, Founder, Ph.D
Charles Cashion, President, MBA
Daniel Ripley, President, MBA
Keith Marshall, President, MBA
Louis Lacasse, Director, MBA
Shahzad Malik, Director
David Hagerty, President

Stock Performance

Conatus Pharmaceuticals Performance Indicators